Cytosorbents Corporation (CTSO) EPS Estimated At $-0.14

Cytosorbents Corporation (NASDAQ:CTSO) Logo
Investors sentiment decreased to 1.29 in Q2 2019. Its down 0.07, from 1.36 in 2019Q1. It dropped, as 7 investors sold Cytosorbents Corporation shares while 17 reduced holdings. 11 funds opened positions while 20 raised stakes. 7.96 million shares or 1.03% less from 8.04 million shares in 2019Q1 were reported.
Barclays Public Ltd Liability invested in 19,740 shares or 0% of the stock. Raymond James & has invested 0% of its portfolio in Cytosorbents Corporation (NASDAQ:CTSO). Credit Suisse Ag reported 0% stake. Goldman Sachs Group Inc Inc holds 10,873 shares or 0% of its portfolio. Spark Investment Mngmt Lc owns 10,800 shares. Bradley Foster Sargent Ct accumulated 118,751 shares or 0.03% of the stock. Creative Planning has invested 0% of its portfolio in Cytosorbents Corporation (NASDAQ:CTSO). Glenmede Tru Na, Pennsylvania-based fund reported 2,161 shares. Bnp Paribas Arbitrage Sa holds 3,392 shares. Charles Schwab Investment Mngmt invested in 0% or 81,270 shares. Wells Fargo Co Mn holds 25,213 shares or 0% of its portfolio. Group Incorporated One Trading L P reported 0% stake. Fincl Bank Of Montreal Can has invested 0% in Cytosorbents Corporation (NASDAQ:CTSO). Deutsche Bancshares Ag owns 23,936 shares for 0% of their portfolio. Cwm Lc holds 0% of its portfolio in Cytosorbents Corporation (NASDAQ:CTSO) for 362 shares.

Since August 16, 2019, it had 1 insider purchase, and 0 insider sales for $31,395 activity.

Analysts expect Cytosorbents Corporation (NASDAQ:CTSO) to report $-0.14 EPS on November, 5.They anticipate $0.04 EPS change or 40.00 % from last quarter’s $-0.1 EPS. After having $-0.11 EPS previously, Cytosorbents Corporation’s analysts see 27.27 % EPS growth. The stock increased 3.67% or $0.18 during the last trading session, reaching $5.09. About 108,926 shares traded. Cytosorbents Corporation (NASDAQ:CTSO) has declined 40.00% since October 7, 2018 and is downtrending. It has underperformed by 40.00% the S&P500.

CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent, porous polymer technology. The company has market cap of $163.75 million. The Company’s principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. It currently has negative earnings. The firm also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.

More notable recent Cytosorbents Corporation (NASDAQ:CTSO) news were published by: Finance.Yahoo.com which released: “CytoSorbents to Participate at the B. Riley FBR 20th Annual Institutional Investor Conference – Yahoo Finance” on May 20, 2019, also Finance.Yahoo.com with their article: “Do Insiders Own Shares In Cytosorbents Corporation (NASDAQ:CTSO)? – Yahoo Finance” published on June 26, 2019, Prnewswire.com published: “Israel Approves CytoSorb Registration, CytoSorbents Announces Gad Medical as Distributor – PRNewswire” on March 25, 2019. More interesting news about Cytosorbents Corporation (NASDAQ:CTSO) were released by: Finance.Yahoo.com and their article: “Knoll (KNL) Q2 Earnings and Revenues Top Estimates – Yahoo Finance” published on July 24, 2019 as well as Finance.Yahoo.com‘s news article titled: “Why Hospitality Properties Trust (NASDAQ:HPT) Could Be Worth Watching – Yahoo Finance” with publication date: June 24, 2019.

Cytosorbents Corporation (NASDAQ:CTSO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.